Skip to main content

Mylan Laboratories


affirmed its fiscal 2004 earnings guidance Monday and also said it has started selling a generic version of



Scroll to Continue

TheStreet Recommends

heartburn treatment Prilosec.

In a press release, Mylan said it expects fiscal 2004 earnings of $1.67 to $1.77 a share. Additionally, the company's Mylan Pharmaceuticals unit has started selling 10 mg and 20 mg omeprazole delayed-release capsules, the generic version of Prilosec.

Shares of Mylan were gaining 93 cents, or 2.8%, to $34.48 in recent

New York Stock Exchange


On average, analysts polled by Thomson First Call expect Mylan to earn $1.62 a share in fiscal 2004, which is already underway.